JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - Oscar Health (NYSE: OSCR) reported fourth quarter EPS of $-0.62, $0.02 worse than the analyst estimate of $-0.60. Revenue for the quarter came in at $2.39B versus the consensus estimate of $2.46B.
Guidance
Oscar Health sees FY 2025 revenue of $11.20B-$11.30B versus the analyst consensus of $11.69B.
Oscar Health’s stock price closed at $15.27. It is up 12.78% in the last 3 months and up 16.48% in the last 12 months.
Oscar Health saw 1 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Oscar Health’s stock price’s past reactions to earnings here.
According to InvestingPro, Oscar Health’s Financial Health score is "great performance".
Check out Oscar Health’s recent earnings performance, and Oscar Health’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar